96 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
5 Mar 24
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
7:31am
:
Operating expenses:
Research and development
In process research and development
General and administrative
Total operating expenses
Loss from operations … equivalents and marketable securities will be sufficient to fund operating and capital expenditures into the first half of 2026.
Research
8-K
EX-99.1
GOSS
Gossamer Bio Inc
9 Nov 23
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
7:31am
half of 2026.
Research and Development (R&D) Expenses: For the quarter ended September 30, 2023, R&D expenses were $31.2 million, compared to $44.5 … months ended September 30,
Nine months ended September 30,
Operating expenses:
Research and development
In process research and development
General
424B3
5m32v9 z6
28 Aug 23
Prospectus supplement
4:29pm
S-3
lv4g j8tivxw3
18 Aug 23
Shelf registration
8:41am
S-3ASR
5z8sw5 ngvskj
17 Aug 23
Automatic shelf registration
4:01pm
8-K
EX-99.1
zvm mzlf7lriwz
8 Aug 23
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
4:01pm
8-K
EX-99.1
plmgfrx
20 Jul 23
Interim TORREY OLE Update and PROSERA Phase 3 Design July 2023
7:50am
8-K
EX-99.1
v9s krbei7lzus3yjb4
9 May 23
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
4:03pm
PRE 14A
hfjteg3jehyp
17 Apr 23
Preliminary proxy
4:01pm
8-K
EX-99.1
vzr2 myo5g5e
3 Nov 22
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
4:00pm
8-K
EX-99.1
3bk450
9 Aug 22
Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update
8:08am
S-3ASR
w7ey2mrwkltd0ttad
9 Aug 22
Automatic shelf registration
12:00am